Cutler Group LP Chemo Centryx, Inc. Put Options Transaction History

Cutler Group LP

$307 Million
Q1 2024

Put Options

14 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q3 2022 Oct 25, 2022	BUY	$22.17 - $51.8 $77,595 - $181,300	3,500 Added 22.73%	18,900 $7,000
Q2 2022 Aug 04, 2022	SELL	$15.36 - $27.51 $482,304 - $863,814	-31,400 Reduced 67.09%	15,400 $189,000
Q1 2022 Apr 14, 2022	BUY	$22.22 - $39.12 $555,500 - $977,999	25,000 Added 114.68%	46,800 $392,000
Q4 2021 Jan 18, 2022	SELL	$18.38 - $40.5 $169,096 - $372,600	-9,200 Reduced 29.68%	21,800 $166,000
Q3 2021 Oct 26, 2021	SELL	$13.18 - $19.83 $1.03 Million - $1.54 Million	-77,900 Reduced 71.53%	31,000 $315,000
Q2 2021 Jul 19, 2021	BUY	$9.59 - $50.88 $919,681 - $4.88 Million	95,900 Added 737.69%	108,900 $960,000
Q1 2021 Apr 26, 2021	BUY	$49.53 - $68.4 $614,172 - $848,160	12,400 Added 2066.67%	13,000 $91,000
Q4 2020 Jan 21, 2021	SELL	$47.25 - $65.16 $699,300 - $964,368	-14,800 Reduced 96.1%	600 $1,000
Q3 2020 Oct 27, 2020	BUY	$46.35 - $61.69 $672,075 - $894,505	14,500 Added 1611.11%	15,400 $40,000
Q2 2020 Jul 22, 2020	SELL	$38.58 - $65.07 $146,604 - $247,265	-3,800 Reduced 80.85%	900 $1,000
Q1 2020 May 07, 2020	BUY	$32.73 - $50.78 $137,466 - $213,276	4,200 Added 840.0%	4,700 $36,000
Q3 2019 Oct 28, 2019	BUY	$6.47 - $8.96 $3,235 - $4,480	500 New	500 $0
Q1 2018 May 11, 2018	SELL	$5.9 - $14.99 $11,800 - $29,980	-2,000 Closed	0 $0
Q3 2017 Oct 17, 2017	BUY	$6.5 - $10.69 $13,000 - $21,380	2,000	2,000 $0

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.